Caplin Point Q3 FY26: PAT up 18% YoY, 9M PAT up 20.5%

Ebitda Margin ExpansionResults View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1920.00

prior close

₹1904.40

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%-0.0% vs market

Pharmaceuticals peers, median of 157sector-0.5%-0.6% vs sector

On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

+0.4

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-1.0-0.0-0.5-0.6

Next day

-4.5-1.4-3.1-1.2-3.3

-8.2+1.1-9.4+0.6-8.8

-9.7+1.6-11.3+1.0-10.7

-9.0+1.8-10.8+0.9-9.9

-9.8+1.0-10.9+0.1-9.9

-10.5-0.6-9.9-1.4-9.2

15d

-10.1-0.2-9.9-2.9-7.2

-13.4-3.8-9.6-5.0-8.4

-18.2-7.5-10.7-7.3-10.9

-10.0+5.2-15.2+0.4-10.4

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q3 FY26 revenue from operations at 543 crore rupees, up 10.1% YoY. 9M FY26 revenue at 1,587 crore rupees, up 10.6% YoY. 9M EBITDA at 644 crore rupees with margin expanding to 38.5% from 36.5% YoY. 9M PAT at 477 crore rupees, up 20.5% YoY. Basic EPS at 61.98 rupees. US market 9M revenue up 25% to 335 crore rupees. Free cash reserves at 1,381 crore rupees, liquid assets at 2,459 crore rupees. Company is net cash positive with 1,000 crore rupees capex plan funded by internal accruals.

Likely market impact

Strong revenue and PAT growth with EBITDA margin expansion, backed by a net cash balance sheet and ongoing capex for capacity and new platforms.